

METOLAZONE

Indications/Uses

Listed in Dosage.

Dosage/Direction for Use

Adult: PO HTN Initial:1.25 mg/day, adjusted after 3-4 wk. Usual range: 2.5-5 mg/day, either alone or w/ other antihypertensives. Maintenance: 5 mg on alternate days. Oedema 5-10 mg/day, up to 20 mg/day if needed. Max: 80 mg/24 hr.

Administration

Should be taken with food. Take after breakfast.

Contraindications

Anuria; hepatic coma or pre-coma. Pregnancy.

Special Precautions

Pre-diabetes or DM; gout; SLE; hepatic and renal impairment; hypercholesterolaemia. Correct electrolyte disturbances prior to therapy. Risk of cross-sensitivity with sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides and loop diuretics. Lactation.

Adverse Reactions

Chest pain, palpitation, necrotising angitis, orthostatic hypotension, syncope, venous thrombosis, vertigo, volume depletion; depression, dizziness, chills, drowsiness, fatigue, restlessness, headache, lightheadedness; petechiae, photosensitivity, hypersensitivity reactions; gout attacks, electrolyte disturbances; abdominal bloating, diarrhoea, abdominal pain, anorexia, constipation, epigastric distress, nausea, xerostomia, pancreatitis, vomiting; impotence; aplastic anaemia, thrombocytopenia, haemoconcentration, leukopenia; cholestatic jaundice, hepatitis; joint pain, muscle cramps, weakness, neuropathy, paraesthesia; blurred vision; increased BUN, glucosuria.

Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.

Pregnancy Category (US FDA)

B D if used in gestational HTN.

Drug Interactions

Hypotensive and nephrotoxic effects of ACE inhibitors may be enhanced. Absorption may be reduced with bile acid sequestrants. Hyperglycaemic effect may be enhanced with diazoxide. May increase serum concentration and QTc-prolonging effect of dofetilide. May reduce lithium excretion. Hypotensive effect may be increased with alcohol.

CIMS Class

Diuretics

ATC Classification

C03BA08 - metolazone ; Belongs to the class of low-ceiling sulfonamide diuretics.

Disclaimer: This information is independently developed by CIMS based on metolazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com

Available Brands

DIUREM

LAZON

MELA

METADURE

METOLACTONE

METORAL

METOZ

RPMEL

ZYTANIX